News archive
Showing 703 results
May 2008
-
Media Release
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa® in Women With Early-Stage Breast Cancer
- Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone(1)- Findings… -
Media Release
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa® in Women With Early-Stage Breast Cancer
-
Media Release
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70%- RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with… -
Media Release
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
-
Media Release
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
- Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for diverse forms of cancer- Plenary session to highlight impact… -
Media Release
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
March 2008
-
Media Release
VIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
- Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen- Femara only member of aromatase inhibitor class… -
Media Release
VIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
February 2008
-
Media Release
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus- Everolimus (RAD001) tablet, taken once daily,… -
Media Release
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy